Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7951 to 7965 of 8816 results

  1. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

    In development Reference number: GID-TA11443 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development Reference number: GID-TA11301 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]

    Discontinued Reference number: GID-TA11442

    Technology appraisal guidance
    Discontinued

  4. Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [ID6247]

    Discontinued Reference number: GID-TA11251

    Technology appraisal guidance
    Discontinued

  5. Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) (HTG627)

    This guidance has been withdrawn because Cartiva Synthetic Cartilage Implant (SCI) has been recalled, and the evidence for this guidance was based solely on Cartiva SCI. More information is available in the field safety notice issued by Stryker. Surgeons are advised not to implant this device, to return any unused devices to Stryker and to consider reviewing any patients who have had Cartiva SCI. NICE will consider issuing new guidance on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) if evidence using an appropriately CE-marked device becomes available.

    HealthTech guidance
    Published
    1 June 2022

  6. Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)

    This guidance has been updated and replaced by NICE's technology appraisal guidance on cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242) and bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).

    Withdrawn guidance

  7. Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

    This guidance has been updated and replaced by NICE's technology appraisal guidance on bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer (TA1136).

    Withdrawn guidance

  8. Leadless cardiac pacemaker implantation for bradyarrhythmias (HTG484)

    This guidance has been updated and replaced by NICE HealthTech guidance 770.

    HealthTech guidance
    Published
    29 August 2018

  9. Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

    Discontinued Reference number: GID-TA10843

    Technology appraisal guidance
    Discontinued

  10. Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468]

    In development Reference number: GID-TA11581 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]

    In development Reference number: GID-TA11560 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A [ID6312]

    Discontinued Reference number: GID-TA11329

    Technology appraisal guidance
    Discontinued

  13. Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]

    In development Reference number: GID-TA11882 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]

    In development Reference number: GID-TA11157 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

    Discontinued Reference number: GID-TA10259

    Technology appraisal guidance
    Discontinued